Primary human amnion cell monolayers which had been treated with DEAEdextran, washed, and then inoculated with sonicated cells of the EB3 line of Burkitt's lymphoma cells developed foci of transformed amnion cells 7 to I4 days later. When either the DEAE-dextran or the sonicate was omitted, no significant transformation was found. The foci consisted of enlarging mounds of rapidly dividing cells, which upon subculturing continued their high mitotic activity; and strains or lines of the transformed amnion cells were thus readily established. The modal number of chromosomes in such lines was 65 instead of the normal 46. Not all human amnions yielded cells transformable by EB3 cell sonicate, as determined by direct comparisons using the same cultural conditions and testing with the same fresh sonicate preparation in the same experiment. Overall, it appeared that only about 40 to 50 ~ of the amnions yielded transformable cell monolayers; the rest gave monolayers apparently completely refractory to the transformation. The transformed amnion cells contained nuclear and cytoplasmic Epstein-Barr virus (EBV) antigen(s), as revealed by indirect immunofluorescence tests.
INTRODUCTION
Pulvertaft 0964) and Epstein &Barr 0964) were pioneers in the establishment of lymphoblastoid cell lines in continuous culture from samples of Burkitt's lymphoma; and now many such cell lines have been established. In the case of most of these lines, at any one time a small fraction (about o.I ~ to lO ~, depending on the particular line and on the cultural conditions, e.g. the amount of arginine in the medium) of the cells is engaged in the synthesis of a herpes-like virus designated the Epstein-Burr virus (EBV; Epstein, Achong & Burr, 1964; Epstein et al. 1965; Henle & Henle, 1966, I968) . The virus can be detected in these cells by specific immunofluorescence using sera containing antibodies to EBV capsid antigen, and by electron microscopy. These cell lines are in an EBV carrier state.
The great majority of EBV virions found by electron microscopy in Burkitt's lymphoma cell lines appear to be defective or immature (Henle, Hummeler & Henle, I966 ) , and might be expected to be non-infective, at least under the usual test conditions. Though most, and sometimes nearly all, of the Burkitt's lymphoma cells do not contain even immature or defective EBV virions detectable by electron microscopy, there is good evidence that all or nearly all of the cells do possess the capacity to synthesize EBV virions, and that this capacity is transmitted vertically to both daughter cells at each mitotic cell division (Maurer, Imamura & Wilbert, 197o; Zajac & Kohn, 197o) . The physical determinant of this capacity is probably the EBV DNA genome in the Burkitt's lymphoma cells, since the EBV DNA, or at least part of it, can be demonstrated in an EBV virion-free line (Raji) of Burkitt's lymphoma cells (average of about 6 EBV virion DNA genome equivalents per Raji cell) by specific DNA-DNA hybridization procedures 197o) .
We undertook the experimental work reported herein with the idea that lysates of cells of Burkitt's lymphoma cell lines would be expected to contain a probably far higher concentration of various EBV subviral units, including EBV DNA itself, than of mature, nondefective EBV virions, and that many of these subviral units might possess potential transforming activity, revealable by using a transfection method. As host cells, we chose primary human amnion cell monolayers, because of their property of growing as strict monolayers without spontaneous piling of cells, and because, hopefully, the transformed cells would manifest themselves by growing into readily enumerable foci or mounds of cells, as is the case with several animal tumour viruses on certain cell monolayers.
The technical key to this work is probably the use of DEAE-dextran to sensitize the cells. Pagano & Vaheri (I965) discovered that DEAE-dextran is a very effective enhancer of the transfection of cultured primate cells by poliovirus RNA. More recent work has shown that DEAE-dextran gives the most enhancement of transfection when the primate cell sheets are incubated briefly with the DEAE-dextran and then rapidly washed with buffer and immediately inoculated with the viral nucleic acid (A1-Moslih & Dubes, I973a ).
It turned out that a cell-transforming agent was found in lysates of the EB 3 line, which is an EBV-carrying line (Henle et al. 1966 ) of Burkitt's lymphoma cells, and that this agent gave significant transformation of human amnion cells only when these cells had been sensitized by pre-treatment with DEAE-dextran. It is the purpose of this report to describe the transformation observed, and to give some of the properties of the transforming agent. In addition, the results of tests of the EB 3 cell lysates on rodent cells (secondary rat embryo cell monolayers) will be given.
A summary of part of this work was presented at the annual meeting of the American Society for Microbiology in Chicago, II1., on 15 May, I974 (A1-Moslih & White, I974). Secondary rat embryo (RE) cell monolayers were grown from cell suspensions obtained by trypsin dispersion of primary monolayers purchased from Flow Laboratories, Rockville, Md. Growth medium was the basal medium of Eagle (BME) with Io ~ calf serum, or MEM with Io ~ calf serum.
The HA and RE monolayers were grown in plastic Petri dishes in a humidified atmosphere of 95 ~ air and 5 ~ carbon dioxide.
The EB 3 line of Burkitt's lymphoma cells was obtained from Flow Laboratories, and was grown in suspension in MEM containing IO ~ calf serum in sealed rcller bottles.
Primary human leucocyte cultures were grown from peripheral blood leucocytes obtained from two healthy adults (one woman and one man), neither of whom had a past history of Burkitt's lymphoma or infectious mononucleosis. The leucocytes were obtained from 1o to 2o ml of blood and were used after 3 to 4 days of pre-treatment with phytohaemagglutinin-M, as described by Miller & Enders 0968) . Growth medium was MEM with 1o ~ calf serum.
All cells were grown at 37 °C.
DEAE-dextran.
DEAE-dextran of lot number TO 5469 was purchased from Pharmacia, Uppsala, Sweden. This lot had been made from dextran of average mol. wt. 2 x lO 6. A stock solution containing Io mg/ml was prepared in de-ionized distilled water and sterilized by autoclaving.
Enzymes. Trypsin (EC 3.4.4.4 ; crystallized twice), c~-chymotrypsin (EC 3.4-4.5; from beef pancreas, crystallized 5 times), and bovine pancreatic ribonuclease (RNase; EC z.7.7. ~6; crystallized 5 times, salt free) were obtained from Mann Research Laboratories, Inc., New York, N.Y. Electrophoretically purified deoxyribonuclease (DNase; EC 3.I.4.5) was obtained from Sigma Chemical Co., St Louis, Mo. Each enzyme was prepared in de-ionized distilled water to contain 5oo/zg/ml.
Sonication of cells.
A suspension (lO 6 cells/ml) of EB 3 cells which had been grown for 5 to 7 days was sonically treated with a Biosonik IV needle probe, at 7o ~ of the maximum low-range power, for 5 min in I min bursts. This procedure was carried out in an icewater bath. Microscopic examination of the sonicates revealed no intact cells. The sonicates were held at o °C until used, which was usually less than a h later. Control sonicates of normal primary human leucocytes were prepared in the same way from cell suspensions (lO 6 cells/ml) grown similarly.
Treatments of sonicates with enzymes. Samples of EB 3 cell sonicates were treated individually with DNase, RNase, trypsin, or c~-chymotrypsin. The treatments were done by diluting the sonicate sample twofold into enzyme solution such that, after this dilution, the concentration of enzyme was 5, xo or 5o #g/ml (for specific values see Table 6 ); and the mixture was then incubated at 13 °C for 4o rain, prior to testing its capacity to transform HA cells. A diluent control was done in exactly the same way as the enzyme tests except that no enzyme was added.
Also, in the cases of DNase and trypsin, unincubated controls were done; that is, the mixtures as described above were made, but immediately after mixing they were inoculated on to the HA cell monolayers for the transformation tests.
Treatments ofsonicates with sera. Samples of EB3 cell sonicates were diluted twofold into test serum preparations such that, after this dilution, the concentration of the test serum was 2 ~; and the mixtures were then incubated at 23 °C for 3o min, prior to testing their capacity to transform HA and RE cells. Two test sera were used: an EBV-positive (titre 1:200) serum and an EBV-negative (titre I "< IO) serum. For further information on these sera, see the subsection below on immunofluorescence. Diluent control, using Hanks' balanced salt solution (BSS), was done in exactly the same way except that test serum was omitted.
Transformation tests. HA and RE monolayers were pre-treated with DEAE-dextran according to the methods previously described (A1-Moslih & Dubes, I973a, b) . After the washings to remove the free DEAE-dextran from the cell monolayers, they were inoculated with sonicate, or treated sonicate, o'3 ml/dish, and incubated at 23 °C for I5 min, or in some instances at 37 °C for 2 h. The monolayers were then washed with the phosphatebuffered saline (PBS) of Dulbecco & Vogt (I954) , fed maintenance medium, and incubated in a humidified atmosphere of 5 ~ CO2 and 95 9/00 air at 37 °C for I4 days, during which time the monolayers were periodically examined for foci of proliferating cells.
Except for the tests of calcium effect, the maintenance medium was MEM with IO calf serum, except that in some tests with HA cells lactalbumin hydrolysate medium (LAH) containing 2 ~o calf serum was used.
To test the effect of calcium, the maintenance medium used for the first two days after inoculation was MEM with 5 ~ calf serum and supplemented with the non-essential amino acids; and thereafter some of the monolayers were fed this medium, while others received this medium minus its CaC12 component. This protocol, which is essentially the same as that of Williams & Ustacelebi (I970, is based on the original work of Freeman et al. (I967) .
Immunofluorescence studies. The indirect immunofluorescent antibody staining procedure described by Henle & Henle (I966) was used. Cells of transformed HA cell lines, derived from proliferating cell loci on monolayers which had been inoculated with EB 3 cell sonicate, were scraped from culture bottles, placed on slides, fixed with acetone, incubated with one of the human test sera, and then treated with fluorescein isothiocyanate-conjugated goat or guinea pig anti-human globulin antibody preparation, which was purchased from Microbiological Associates, Bethesda, Md.
Control slides of normal untransformed HA cells were prepared similarly. Eight human test sera, obtained from patients at the University of Nebraska Medical Center, were used. These sera were titrated for antibody to EBV by the Communicable Disease Centre, Atlanta, Ga., using the indirect fluorescent antibody technique; these titrations showed that four of the test sera contained antibodies to EBV, while such antibodies were undetectable in the other tour sera (titres i:< IO). The four sera with antibodies had the following titres: I : IOO; I : 4o; I : 40; I : 8o. Thus, for the immunofluorescence tests with the transformed HA cells, four of the human test sera used were EBV immune (experimentals) and the remaining four were control non-immune sera.
Chromosome analysis. A modification of techniques described by Jenkins, Eisen & Sequin (I971) and Rothfels & Siminovitch (2958) Arithmetic mean number of transformed HA cell foci per platet A * Cells were pre-treated at 23 ° C for 9 min, then rapidly washed three times with medium A, which is PBS minus CaCla and MgC12, 4 ml/wash/cell sheet, and inoculated immediately with sonicate or medium control.
t Two or three plates were used per determination.
RESULTS

Transformation of HA cells by EB 3 cell sonicate
In the first experiments of this project, HA cell monolayers which had been pre-treated with DEAE-dextran were found to be sensitive to transformation by EB 3 cell sonicate (Tables I and 3 ). When the sonicate was omitted, or substituted by medium, no transformation was obtained.
The pre-treatment of the cells with DEAE-dextran enormously increased their sensitivity to transformation by the EB3 cell sonicate (Tables I and 3 ). In all the tests run, a total of only one transformed HA cell focus was found on the monolayers which had not been pretreated with DEAE-dextran before inoculating them with EB 3 cell sonicate.
When the pre-treatment with DEAE-dextran was at 2 3 °C for 9 rain, a DEAE-dextran concentration of Ioo/~g/ml was superior to that of Iooo/~g/ml for sensitizing the HA cell monolayers (Table I) .
The foci of transformed HA cells began to be apparent at about 7 days after inoculation, and continued to increase in number until about the fourteenth day after inoculation. The foci increased rapidly in size, typically increasing from about 30 to 35o #m in diam. in 3 to 5 days. Cells in the foci appeared to pile up to form 'colonies' with domed centres. Such loci are shown in Fig. I .
Variability among human amnions in sensitivity of their derived HA monolayers to transformation
Some of the follow-up experiments to the original HA cell transformation experiments gave no transformed HA cell foci, and we began to suspect that some amnion cell batches were refractory to transformation by EB 3 cell sonicate. This was indeed found to be the case. In each of two experiments, placentas were obtained on the same day, and the HA cell were then dispersed and grown under identical conditions. The cell batches from the different placentas were then compared to each other in sensitivity to transformation by the same fresh EB3 cell sonicate. The results (Table 2) showed that only two of the five amnion cell batches tested in the two experiments were transformable by EB3 cell sonicate. Thus, some feature of the source amnion from which the HA cell monolayers were obtained strongly influenced their transformability.
Over the entire course of this research project, we have found that only about 40 to 50 of the human amnions yield cell batches transformable by EB 3 cell sonicate. 
Transformation of RE cells by EB3 cell sonicate
Later experiments showed that RE cell monolayers could also be sensitized by D E A Edextran to transformation by EB3 cell sonicate. N o transformed RE cell foci were obtained when either the pre-treatment of the cells with DEAE-dextran or the inoculation of the cells with the EB 3 cell sonicate was omitted (Table 3) .
The time of appearance and the rate of growth of the transformed cell foci were similar for the R E and H A foci. Transformed RE cell foci are shown in Fig. 2 unstained spots or islands within the transformed cell focus in Fig. 2a . Such islands were typical of transformed RE loci, but were not observed in transformed HA foci. The nature of the islands is unknown. No batch of secondary RE cell monolayers refractory to transformation by EB 3 cell sonicate was encountered; however, it should be noted that all the RE experiments were done with just two such cell batches.
Effect of calcium on the number of transformed cell foci observed
A different kind of maintenance medium (see Methods sections) was used to test the possibility that the number of transformed cell foci found would be markedly increased by lowering the concentration of calcium in the maintenance medium, as is the case for transformation of rat embryo cells by adenoviruses (Freeman et al. 1967) . The results showed that added CaC12 at 1.8 mM concentration in the maintenance medium greatly decreased the number of transformed cell foci found, both for HA and for RE cells (Table 3) .
Establishment of transformed HA cell lines
Cells obtained from the transformed HA cell foci multiplied rapidly upon subculturing; and the cell cultures obtained could be passaged repeatedly with continued rapid multiplication of the transformed HA cells. Thus, transformed HA cell strains or lines could be easily established. The first such strain or line, designated HA-TI, was obtained in an early experiment, and in June of x974 this line was in its 56th serial passage. A second such line, HA-T2, obtained in a later experiment, was carried through I4 serial passages before being placed in frozen storage. t All cell monolayers had been pre-treated with DEAE-dextran in the same way. Experiments 69 and 70 were done on different days, using different fresh sonicates.
Cells obtained from control untransformed HA cell monolayers, on the other hand, soon ceased multiplying upon subculturing; and thus no control untransformed HA cell strains or-lines could be established.
EBV-specific antigens in transformed HA cells
Approx. 30 to 50 700 of the cells in the transformed HA cell strains or lines were observed to contain in both nuclear and cytoplasmic fluorescence when they were incubated with any one of the four human test sera containing anti-EBV antibodies, prior to adding the fluorescent anti-human globulin antibody preparation. Control tests done in the same way except using four EBV-negative human test sera showed no specific fluorescence. (For information on these eight human test sera, see Methods section.) The transformed cells used in these M.I. AL-MOSLIH~ R. J. WHITE AND G. R. DUBES tests were t¥om the HA-TI line in its 3rd and 56th passages, and from HA-T2 in its I4th passage. Cells from control untransformed HA cell monolayers gave no fluorescent staining after incubation with EBV-positive or EBV-negative sera.
Thus, many of the transformed HA cells contain EBV-specific antigens both in the nucleus and in the cytoplasm, whereas the control untransformed HA cells do not contain EBVspecific antigens.
Chromosome analysis of transformed HA cells
A detailed analysis of HA-TI and HA-T2 cells in their 3rd and 4th passages, respectively, showed that 60 to 7o ~ of the cells contained approx. 65 chromosomes. A karyogram of a typical transformed HA cell is shown in Fig. 3 . No abnormal group C chromosomes with near-terminal secondary constrictions on their long arms were seen.
Lack of transforming activity of sonicate of normal primary human leucocytes
The question arose as to whether presumably normal human leucocytes, as well as the EB3 cells derived from Burkitt's lymphoma, would, upon sonication, yield a cell-transforming agent. We attempted to answer this question by means of two experiments, the results of which (Table 4) showed that the sonicate of the normal leucocytes contained no comparable cell-transforming agent, either for HA or for RE cell monolayers.
Non-neutralizability of transforming agent by EBV-positive serum
The cell-transforming agent present in EB 3 cell sonicate was found to be non-neutralizable by human test serum contaning anti-EBV antibodies (titre I :Ioo; see Methods section; Table 5 ).
Inactivation of transforming agent by specific enzymes
One explanation of the non-nuetralizability of the transforming agent by anti-EBV antibodies is that the agent is of such a subviral nature that either it does not bind these antibodies or the binding exerts no neutralizing effect on cell-transforming activity.
Such a subviral unit of EBV could be devoid of virus envelope, and possibly also devoid Transformation by lysate of lymphoma cells 34I of part or even all of the virus capsid. Subviral units of these kinds might be expected to be destructible by either, or both, proteases or deoxyribonucleases. We found that the inoculation of sensitized HA cell monolayers with EB 3 cell sonicates which had been incubated with either trypsin, a-chymotrypsin, or DNase, at 50/zg/ml, for 40 rain resulted in no transformed foci (Table 6 ). When tested in the same way, RNase did not influence the transformation (Table 6) . Further experiments were done to see if trypsin and DNase were exerting their effects through inactivation of the transforming agent in the sonicate, or through possibly interfering with the cell transformation process per se or with the manifestation of the transformation. In these experiments, the influence of the 4o min incubation of EB3 cell sonicate with the enzyme was assessed, and it was found that these enzymes did not exert transformation-blocking effects when the mixtures of enzyme and EB 3 cell sonicate were inoculated on to the sensitized HA cell monolayers immediately after mixing. Thus, trypsin and DNase act by inactivating the transforming agent.
DISCUSSION
Transformation of normal human leucocytes can be effected by co-cultivating them with lethally X-irradiated cells of the EBV-carrying Jijoye line of Burkitt's lymphoma cells in the presence of a monolayer of the WI-38 strain of human diploid female fibroblasts (Henle et al. 1967; Diehl et al. 1969) . Though EBV itself does not produce any obvious c.p.e, in many standard kinds of tissue culture (Epstein et al. I965) , its infectivity and transforming activity for leucocytes and leucocyte-like cells have been shown. The infectivity of EBV for cells of an established line of human leucocytes from a healthy donor (Gerber, Whang-Peng & Monroe, I969) and for a line of human leukaemia cells and a line of human lymphoblastoid cells (Henle et al. 197o ) has been shown by the development of specific EBV antigens in the cells after their exposure to EBV. Transformation of normal human leucocytes by EBV has been shown using EBV obtained from EBV-carrying Burkitt's lymphoma cell lines and from an EBV-carrying human leukaemia cell line, and partially purified (Pope, Horne& Scott, I968, 1969; Gerber et al. 1969) . The leucocytes transformed either by co-cultivation with the Jijoye cells or by EBV itself become continuously culturable cell lines, containing some cells showing EBV antigens. Both the infectivity and the transforming activity of the EBV preparations can be specifically neutralized by anti-EBV sera. In most cases, the EBV-carrying Burkitt's lymphoma cell lines are diploid or near-diploid, and they often carry in a variable fraction (about I ~ to 50 ~, depending on the line) of their cells one or two abnormal chromosomes of a member (probably chromosome number IO) of the C group (Kohn et aL 1967; Miles & O'Neill, 1967) . The abnormality consists of a nearterminal secondary constriction on the long arms of the chromosome. Though usually only a small minority of the cells show this abnormality at mitotic metaphase, it appears that all, or nearly all, of the cells carry the capacity to express this chromosomal abnormality (Zajac & Kohn, 197o) . It is interesting, and possibly of considerable significance, that the capacity to show this apparently specific abnormal group C chromosome is possessed by the leucocytes transformed either by co-cultivation with the Jijoye cells or by EBV.
Our transformation system described herein differs in three important ways from these systems for transformation of human leucocytes by EBV. First, in our system the cells transformed are cells which normally grow attached to the surface cf the glass or plastic container; second, the transforming agent in our EB 3 cell sonicates is subviral in nature, being completely destructible by either deoxyribonuclease or trypsin, and not neutralized by anti-EBV serum; and third, our transformed cell lines have a modal number (65) of chromosomes much greater than diploid. In addition, we did not see in our transformed amnion cell lines the specific abnormal group C chromosome, though it is quite possible that a small fraction of the cells in our transformed lines do show this abnormal chromosome; it should be noted in this regard that other workers have reported markedly different percentages of EB3 cells showing this abnormal chromosome, e.g. 2 ~ to 3 % by Miles & O'Neill (1967) versus 30 % by Kohn et al. (I967) . We feel that our transformation system may have three important advantages over the earlier transformation systems: (I) The transformed cell loci can be counted, giving a much more efficient measurement of transformation; (2) we would expect the method to be effective even for EBV genome-carrying cell lines devoid of EBV virions; (3) our system, employing a transfection method, would be expected to show a much wider host range for transformation.
Using a procedure markedly different from ours, Glaser & Rapp (1972) It will be interesting to determine the activity of our transformed cells in vivo; such determinations with the transformed rat embryo cells would be especially feasible and significant. A rat 'autograft' model in which cells obtained from a rat are transformed in vitro and then inoculated back into the same rat seems particularly attractive and might eventually be practicable.
It would be difficult to over-emphasize the importance of pre-treating the monolayer cells with DEAE-dextran. Without such pre-treatment, the sensitivity of the monolayer cells to transformation by the agent in EB 3 cell sonicate was very low or zero. Moreover, Epstein et al. (1965) observed no effect, cytopathic or otherwise, on primary human amnion monolayers examined for 2 to 3 weeks after inoculating them with EBV; no transfection methods were used in this early study. There is precedent for the enhancement by DEAE-dextran of the activity of a deoxyribonuclease-labile, trypsin-labile subviral unit not neutralizable by antiviral serum: Such units prepared from adenovirus by heat-shock (e.g., 70 °C, 2o s) are not infective for cultured cells under ordinary plating conditions, but are infective when DEAE-dextran is used (Dubes, Roegner & Cronn, I968 ) . This infective unit is derived from the adenovirion itself, and, based on electron microscopic evidence, is probably the virion core to which some relatively small aggregates of capsomeres may be attached (A1-Moslih et al. I975). DEAE-dextran has also been employed to demonstrate the transfectivity of linear (i.e. unclosed) DNA extracted from cells which had been transformed by simian virus number 4 ° (SV4o; Boyd & Butel, 1972) ; the product of the transfection was apparently SV4o virions containing their closed DNA.
Freeman et al. (1965, I966) discovered that cultures of adenovirus-transformed cells are inhibited by calcium even at only moderate concentrations, e.g. the 1.8 mM concentration of calcium in Earle's balanced salt solution. The inhibition is manifested by clumping of the celts, by their retraction from the glass surface, by their balling up, and apparently by their eventual detachment from the glass, and subsequent loss at changing the culture medium. The adenovirus-transformed cells were, however, readily culturable under low-calcium (e.g. CaCI~ at o. I mi) medium. Cells from 9 out of 9 oncornavirus-transformed cell lines, 8 out of 9 papovavirus-transformed cell lines, and 15 out of 25 control cell lines with no known virus history, did not show such sensitivity to calcium (Freeman et al. 1966) ; thus calcium sensitivity appears to be a rather special property of adenovirus-transformed cells. Our results, however, suggest that calcium sensitivity may extend to some herpesvirustransformed cell lines.
The specific immunofluorescence observed after fixation in the transformed HA cells indicates the presence of EBV antigen(s) in these cells; we do not yet know, however, which EBV antigen(s), e.g. the viral capsid antigen of Henle & Henle (I966) and Henle et al. (1966) or an early antigen produced by the virus (Henle et al. 197o) , is present.
The fact that the activity of the transforming agent in EB3 cell sonicate is completely destructible by either DNase or trypsin, but not by RNase, strongly suggests that the agent is composed of DNA and protein, both of which are accessible to hydrolysis by these enzymes. This finding and the fact that the transforming agent cannot be neutralized with anti-EBV serum exclude the hypothesis that the transforming agent is simply the intact EBV virion, or such a virion modified but still neutralizable by antiserum. However, since the transforming agent was not found in sonicates of cultured normal human leucocytes, but only in sonicates of the EB 3 cells, it seems likely that the transforming capacity is closely connected with the EBV-infected status of the EB3 cells. EB 3 cell sonicate also shows the activity of conferring on treated amnion cells the capacity to make EBV antigen(s), and it seems reasonable to conclude that the entity responsible for this activity contains at least part of the EBV DNA.
The simplest (but not the only) interpretation of these several findings is that the transforming agent and the entity conferring the antigen-synthesizing capacity are one and the same physical particle, and that this particle is part or all of the EBV DNA plus attached protein. (The possibility that the particle also contains host-cell DNA cannot be excluded.) It will be desirable to test this hypothesis by passing EB3 cell sonicate through a good physical separation process, such as equilibrium density gradient ultracentrifugation, to see if these two activities co-migrate, or are physically separable.
The fact that some human amnions yield cell monolayers transformable by EB3 cell sonicate, while other human amnions yield monolayers refractory to such transformation, strikes us as a finding of possibly considerable significance. What amnion property confers such resistance to the transformation? Five possibilities come to mind: such resistance might be related to (a) the immunological status of the mothers, (b) drugs and other medications taken by the mothers, (e) the genotype of the amnion cells, (d) the possibility of a latent viral infection of the amnion cells, or (e) the age of the placenta.
In future experiments, it will be interesting to see if an agent similar to or the same as the transforming agent in EB 3 cell sonicate can be obtained from other cell lines known to carry the EBV genome, e.g. the EBL Jijoye, and QIMR-GOR lines of Burkitt's lymphoma cells, and especially the Raji line, which usually seems to contain no EBV virions, as well as to compare any agents from the QIMR-GOR and QIMR-WIL lines, which seem to contain EBVs with different leucocyte-transforming kinetics (Pope et al. 1969) . Other interesting possible sources would be leucocytes from patients with infectious mononucleosis and cells from human nasopharyngeal carcinomas. However, it should be emphasized that, when human amnion cell monolayers are used to detect the transforming agent in sonicates of such possible source cells, the batch of amnion cell monolayers from each individual amnion used should be tested for transformability by sonicate known to contain the transforming agent, i.e. EB 3 cell sonicate. 
